Exencial Wealth Advisors LLC lifted its position in shares of Colgate-Palmolive (NYSE:CL) by 7.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 81,955 shares of the company’s stock after buying an additional 5,986 shares during the quarter. Colgate-Palmolive makes up 1.3% of Exencial Wealth Advisors LLC’s holdings, making the stock its 17th largest holding. Exencial Wealth Advisors LLC’s holdings in Colgate-Palmolive were worth $5,487,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Palisade Asset Management LLC boosted its holdings in Colgate-Palmolive by 0.6% in the third quarter. Palisade Asset Management LLC now owns 141,610 shares of the company’s stock worth $9,481,000 after acquiring an additional 795 shares in the last quarter. DF Dent & Co. Inc. boosted its holdings in Colgate-Palmolive by 7.1% in the second quarter. DF Dent & Co. Inc. now owns 12,125 shares of the company’s stock worth $786,000 after acquiring an additional 800 shares in the last quarter. Hugh Johnson Advisors LLC boosted its holdings in Colgate-Palmolive by 8.0% in the second quarter. Hugh Johnson Advisors LLC now owns 10,861 shares of the company’s stock worth $704,000 after acquiring an additional 801 shares in the last quarter. West Oak Capital LLC boosted its holdings in Colgate-Palmolive by 3.2% in the third quarter. West Oak Capital LLC now owns 27,049 shares of the company’s stock worth $1,811,000 after acquiring an additional 830 shares in the last quarter. Finally, Heritage Way Advisors LLC boosted its holdings in Colgate-Palmolive by 2.8% in the second quarter. Heritage Way Advisors LLC now owns 31,733 shares of the company’s stock worth $2,057,000 after acquiring an additional 875 shares in the last quarter. 75.08% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:CL opened at $60.23 on Tuesday. Colgate-Palmolive has a 52-week low of $57.41 and a 52-week high of $77.91. The stock has a market capitalization of $52.29 billion, a PE ratio of 20.99, a PEG ratio of 2.96 and a beta of 0.75. The company has a debt-to-equity ratio of 64.85, a current ratio of 1.11 and a quick ratio of 0.77.
Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, October 26th. The company reported $0.72 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.72. Colgate-Palmolive had a return on equity of 12,004.60% and a net margin of 13.55%. The firm had revenue of $3.85 billion during the quarter, compared to analysts’ expectations of $3.89 billion. During the same period last year, the business posted $0.73 earnings per share. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. As a group, equities analysts predict that Colgate-Palmolive will post 2.96 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 15th. Stockholders of record on Friday, October 19th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend is Thursday, October 18th. Colgate-Palmolive’s payout ratio is 58.54%.
Several equities research analysts have weighed in on CL shares. Zacks Investment Research downgraded Colgate-Palmolive from a “hold” rating to a “sell” rating in a report on Friday, October 5th. Wells Fargo & Co lowered their price target on Colgate-Palmolive from $64.00 to $62.00 and set a “market perform” rating for the company in a report on Wednesday, October 17th. Citigroup lowered their price target on Colgate-Palmolive from $70.00 to $68.00 and set a “neutral” rating for the company in a report on Tuesday, July 31st. SunTrust Banks downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating and lowered their price target for the stock from $80.00 to $65.00 in a report on Friday, October 26th. Finally, JPMorgan Chase & Co. downgraded Colgate-Palmolive from a “neutral” rating to an “underweight” rating and lowered their price target for the stock from $61.00 to $54.00 in a report on Monday, October 29th. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and two have assigned a buy rating to the company’s stock. Colgate-Palmolive presently has a consensus rating of “Hold” and a consensus price target of $68.06.
In other news, Vice Chairman Dennis J. Hickey sold 120,000 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $65.72, for a total value of $7,886,400.00. Following the completion of the transaction, the insider now directly owns 202,414 shares in the company, valued at $13,302,648.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Henning I. Jakobsen sold 1,015 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $67.05, for a total value of $68,055.75. Following the completion of the transaction, the chief financial officer now owns 36,193 shares of the company’s stock, valued at $2,426,740.65. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 169,585 shares of company stock valued at $11,132,140. Company insiders own 1.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Exencial Wealth Advisors LLC Purchases 5,986 Shares of Colgate-Palmolive (CL)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/06/exencial-wealth-advisors-llc-purchases-5986-shares-of-colgate-palmolive-cl.html.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.
Recommended Story: Short Selling
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.